CALL/REGENERON PHARMACEUTICALS/800/0.01/17.01.25 Share Price

Warrant

DE000GP371F0

Market Closed - BOERSE MUENCHEN 19:27:03 28/06/2024 BST
2.71 EUR +0.74% Intraday chart for CALL/REGENERON PHARMACEUTICALS/800/0.01/17.01.25
1 month+37.56%
3 months+28.44%
Date Price Change
28/06/24 2.71 +0.74%
27/06/24 2.69 -5.28%
26/06/24 2.84 -2.07%
25/06/24 2.9 +3.57%
24/06/24 2.8 +3.70%

Real-time BOERSE MUENCHEN

Last update June 28, 2024 at 07:27 pm

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying REGENERON PHARMACEUTICALS, INC.
Issuer Goldman Sachs
WKN GP371F
ISINDE000GP371F0
Date issued 21/04/2023
Strike 800 $
Maturity 17/01/2025 (201 Days)
Parity 100 : 1
Emission price 1.34
Emission volume N/A
Settlement Por diferencias
Currency EUR

Technical Indicators

Highest since issue 2.94
Lowest since issue 0.75
Delta0.91x
Omega 3.323
Premium3.48x
Gearing3.65x
Moneyness 1.314
Difference Strike -251 $
Difference Strike %-31.38%
Spread 0.05
Spread %1.85%
Theoretical value 2.685
Implied Volatility 33.61 %
Total Loss Probability 13.87 %
Intrinsic value 2.344
Present value 0.3413
Break even 1,087.59 €
Theta-0.01x
Vega0.01x
Rho0.03x

Company Profile

Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Sector
-
More about the company

Ratings for Regeneron Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Regeneron Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,051 USD
Average target price
1,051 USD
Spread / Average Target
+0.04%
Consensus